GLP-1 receptor agonists (GLP-1 RAs) have been shown to lower MASH disease activity, evidenced by histological improvements in inflammation and hepatocellular ballooning, as well as decreases in liver fat and MASH biomarkers [111]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.